Home › Schizophrenia › NCT06961968
Randomized Withdrawal Study in Patients With Schizophrenia
RecruitingPhase 3
A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: * Males or females 18 to 65 years of age (inclusive) * Diagnosed with schizophrenia per DSM-5 criteria * In need of ongoing psychiatric treatment Exclusion Criteria: * DSM-5 diagnosis of a psychiatric disorder other than schizophrenia that was the primary focus of treatment within the previous six months
About the study
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
What is being tested
- iloperidone (drug)
- placebo (drug)
Sponsor: Vanda Pharmaceuticals · Participants: 400 · Started: May 14, 2025
Contact the study team
- Vanda Pharmaceuticals Inc. · Phone: 202-734-3400
Official record on ClinicalTrials.gov — NCT06961968
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.